New paradigms for the treatment of cancer: The role of anti-angiogenesis agents

https://doi.org/10.1016/S0065-230X(00)79001-4Get rights and content

Abstract

Angiogenesis, the sprouting of new blood vessels, plays a role in diverse disease states including cancer, diabetic retinopathy, age-related macular degeneration, rheumatoid arthritis, psoriasis, atherosclerosis, and restenosis. With regard to cancer, the clinical association of tumor vascularity with tumor aggressiveness has been clearly demonstrated in numerous tumor types. The observation of increased microvessel density in tumors not only serves as an independent prognostic indicator, but also suggests that anti-angiogenic therapy may be an important component of treatment regimens for cancer patients. The complexity of the angiogenic process, which involves both positive and negative regulators, provides a number of targets for therapy. Many positive regulators, including growth factor receptors, matrix metalloproteinases, and integrins, have been correlated with increased vascularity of tumors and poor prognosis for patient survival. Thus, these serve as ideal targets for anti-angiogenesis therapy. Many inhibitors of these targets are currently undergoing clinical evaluation as potential anti-cancer agents. In this article, we discuss the role of positive regulators in angiogenesis and tumor growth and describe the anti-angiogenic agents under development.

References (227)

  • K. Anan et al.

    Surgery

    (1996)
  • K. Anan et al.

    Eur. J. Surg. Oncol.

    (1998)
  • J. Balzarini et al.

    FEBS Lett.

    (1998)
  • M. Börset et al.

    Blood

    (1996)
  • P.C. Brooks

    J. Cancer

    (1996)
  • P.C. Brooks et al.

    Cell. (Cambridge, Mass.)

    (1996)
  • B. Casslen et al.

    Eur. J. Cancer

    (1991)
  • A. Emoto et al.

    J. Urol.

    (1997)
  • W. Fang et al.

    J. Biol. Chem.

    (1992)
  • W. Fiedler et al.

    Blood

    (1997)
  • K. Fujimoto et al.

    Eur. J. Cancer

    (1998)
  • K. Fujisaki et al.

    Am. J. Gastroenterol.

    (1998)
  • D. Hanahan et al.

    Cell (Cambridge, Mass.)

    (1996)
  • Y. Hasui et al.

    Urology

    (1996)
  • I. Hyodo et al.

    Eur. J. Cancer

    (1998)
  • S. Iida et al.

    Biochem. Biophys. Res. Commun.

    (1994)
  • J. Adnane et al.

    Oncogene

    (1991)
  • H. Amaya et al.

    Cancer Lett.

    (1997)
  • I. Anderson et al.
  • H.N. Antoniades et al.
  • A. Ariad et al.

    Breast Cancer Res. Treat.

    (1991)
  • M. Asano et al.

    Cancer Res.

    (1995)
  • A.V. Averbuch
  • C. Bais et al.

    Nature (London)

    (1998)
  • M. Bar-Eli

    Pathobiology

    (1999)
  • E.J. Battegay et al.

    J. Cell Biol.

    (1994)
  • W.T. Bellamy et al.

    Cancer Res.

    (1999)
  • C. Benaud et al.

    Breast Cancer Res. Treat.

    (1998)
  • G. Bergers et al.

    Science

    (1999)
  • J.B. Bhardwaj et al.

    Clin. Cancer Res.

    (1996)
  • A. Bikfalvi et al.

    Bull. Cancer

    (1997)
  • P. Bohlen et al.
  • C. Bouchet et al.

    Br. J. Cancer

    (1994)
  • E. Brambilla
  • P.C. Brooks et al.

    Science

    (1994)
  • P.C. Brooks et al.

    J. Clin. Invest.

    (1995)
  • P.D. Brown et al.

    Hum. Pathol.

    (1995)
  • P.D. Brown et al.

    Am. J. Pathol.

    (1996)
  • P.A. Burke et al.
  • T.R. Burke et al.

    Curr. Pharm. Des.

    (1997)
  • J.A. Byrne et al.

    Mol. Med.

    (1995)
  • J.F. Cajot et al.
  • C.P. Carron et al.

    Cancer Res.

    (1998)
  • M.P. Chenard et al.

    Int. J. Cancer

    (1996)
  • R. Choudhuri et al.

    Cancer Res.

    (1997)
  • K.P. Claffey et al.

    Cancer Res.

    (1996)
  • N.J. Clendennin et al.
  • E. Cornali et al.

    Am. J. Pathol.

    (1996)
  • F. Czubayko et al.
  • B. Davies et al.

    Br. J. Cancer

    (1993)
  • Cited by (0)

    View full text